CD27-CD45+ γδ T cells can be divided into two populations, CD27-CD45int and CD27-CD45hi with little proliferation potential
Creators
- 1. MEDINET Co. Ltd., Yokohama 222-0033 (Japan)
- 2. Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113-8655 (Japan)
Description
In addition to the majority of T cells which carry the αβ T cell receptor (TCR) for antigen, a distinct subset of about 1–5% of human peripheral blood T cells expressing the γδ TCR contributes to immune responses to infection, tissue damage and cancer. T cells with the Vδ2+ TCR, usually paired with Vγ9, constitute the majority of these γδ T cells. Analogous to αβ T cells, they can be sorted into naive (CD27+CD45RA+), central memory (CD27+CD45RA−), effector memory (CD27−CD45RA−), and terminally-differentiated effector memory (CD27−CD45RA+) phenotypes. Here, we found that CD27−CD45RA+ γδ T cells can be further divided into two populations based on the level of expression of CD45RA: CD27−CD45RAint and CD27−CD45RAhi. Those with the CD27−CD45RAhi phenotype lack extensive proliferative capacity, while those with the CD27−CD45RAint phenotype can be easily expanded by culture with zoledronate and IL-2. These CD27-CD45RAhi potentially exhausted γδ T cells were found predominantly in cancer patients but also in healthy subjects. We conclude that γδ T cells can be divided into at least 5 subsets enabling discrimination of γδ T cells with poor proliferative capacity. It was one of our goals to predict the feasibility of γδ T cell expansion to sufficient amounts for adoptive immunotherapy without the necessity for conducting small-scale culture tests. Fulfilling the ≥1.5% criterion for γδ T cells with phenotypes other than CD27−CD45RAhi, may help avoid small-scale culture testing and shorten the preparation period for adoptive γδ T cells by 10 days, which may be beneficial for patients with advanced cancer. - Highlights: • CD27-CD45+ γδ T cells can be divided into two populations, CD27-CD45hi and CD27-CD45int. • CD27-CD45hi γδ T cells are detected in the peripheral blood of both cancer patients and healthy subjects. • CD27-CD45hi γδ T cells are distinct from so-called terminally differentiated CD27-CD45int γδ T cells. • CD27-CD45hi γδ T cells lack vigorous proliferative potential.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.bbrc.2016.08.115Additional details
Identifiers
- DOI
- 10.1016/j.bbrc.2016.08.115;
- PII
- S0006-291X(16)31379-1;
Publishing Information
- Journal Title
- Biochemical and Biophysical Research Communications
- Journal Volume
- 478
- Journal Issue
- 3
- Journal Page Range
- p. 1298-1303
- ISSN
- 0006-291X
- CODEN
- BBRCA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 49046299
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- NEOPLASMS; PATIENTS; PHENOTYPE; POTENTIALS
- Descriptors DEC
- DISEASES
Optional Information
- Copyright
- Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.